AlloVir, Inc. (ALVR) closed the last trading session at $5.43, gaining 14.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Shares of AlloVir (NASDAQ:ALVR) lost ~18% in the premarket on Friday after the cell therapy developer announced an all-stock merger agreement with clinical-stage biopharmaceutical company Kalaris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results